Improved recombinant retroviral titers utilizing trichostatin A

Area of Science:

• Gene Therapy
• Molecular Biology
• Virology

Background:

• Recombinant retroviruses are crucial for gene therapy, enabling exogenous gene delivery to target cells.
• Low retroviral titers limit the number of infected cells and transgene expression, hindering therapeutic efficacy.
• Developing methods to increase retroviral titers is essential for advancing gene therapy applications.

Purpose of the Study:

• To investigate the effect of trichostatin A, a histone deacetylase inhibitor, on the titer of a recombinant retroviral producer cell line.
• To evaluate the potential of trichostatin A as a tool to enhance gene delivery efficiency in gene therapy.

Main Methods:

• An ecotropic producer cell line (psi 2/LIG/NGF) containing mouse nerve growth factor (NGF) and LacZ reporter gene was established.
• The producer cell line was treated with varying concentrations of trichostatin A.
• Retroviral titers were measured using standard methods, and infection efficiency in primary rat marrow stromal cells was assessed.

Main Results:

• Treatment with 3 microM trichostatin A resulted in a 34-fold increase in retroviral titer compared to untreated controls.
• Trichostatin A enhanced retroviral titer 3.4-fold higher than sodium butyrate, a commonly used hyperacetylating agent.
• Infection of primary rat marrow stromal cells increased 5.8-fold when using producer cells treated with trichostatin A.

Conclusions:

• Trichostatin A is a potent enhancer of retroviral titer, offering a significant improvement over existing methods.
• This approach provides a simple and effective strategy to convert low-titer producer cell clones into high-titer clones for gene therapy.
• The findings have direct implications for improving the efficiency and applicability of retroviral gene delivery systems.